Research programme: antibodies - LifeArc/TetraGenetics

Drug Profile

Research programme: antibodies - LifeArc/TetraGenetics

Latest Information Update: 19 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tetragenetics
  • Developer LifeArc; Tetragenetics
  • Class Antibodies; Antihyperglycaemics
  • Mechanism of Action Kv1.3 potassium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Type 1 diabetes mellitus

Most Recent Events

  • 12 Dec 2017 TetraGenetics and LifeArc enters into a collaboration for development of antibodies for Type-1 diabetes mellitus
  • 12 Dec 2017 Early research in Type-1 diabetes mellitus in USA (Parenteral)
  • 12 Dec 2017 TetraGenetics and LifeArc are planning to submit IND for a lead candidate for Type-1 diabetes mellitus at the end of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top